13F Holdings
中文EN

RLYB Rallybio Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1739410 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-32.0%
TTM net income YoY289.2%
TTM EPS YoY145.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,580.9%
Net margin6,177.4%
FCF margin—
EBITDA margin-5,579.0%

Returns

ROE34.5%
ROA32.8%
ROIC (approx.)-149.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets3.4%
Debt / equity0.00x
Current ratio28.87x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$858,000$636,000———
R&D expense$19.60M$41.51M$53.54M$40.69M$26.91M
SG&A expense$14.32M$19.62M$25.39M$27.20M$18.74M
Operating income-$33.06M-$60.50M-$78.93M-$67.88M-$45.65M
Interest expense———$0$10,000
Pretax income-$8.98M-$55.54M-$72.52M-$65.58M-$45.51M
Income tax$0$0$0$0$0
Net income-$8.98M-$57.77M-$74.56M-$66.65M-$47.01M
EBITDA-$32.97M-$60.37M-$78.78M-$67.72M-$45.54M
EPS (basic)-1.59-10.61-1.84-2.09-1.84
EPS (diluted)-1.59-10.61-1.84-2.09-1.84
Weighted avg. shares (diluted)5.63M5.44M40.45M31.82M25.52M
Balance sheet
Cash & equivalents$31.37M$13.90M$24.49M$56.96M$175.33M
Short-term investments$23.36M$51.61M$85.44M$112.04M$0
Current assets$61.25M$67.84M$114.79M$179.50M$180.87M
PP&E, net$23,000$115,000$246,000$385,000$511,000
Total assets$62.26M$68.11M$115.62M$180.44M$182.19M
Current liabilities$4.22M$6.24M$9.26M$10.74M$6.55M
Total liabilities$4.30M$6.45M$9.44M$11.12M$6.58M
Shareholders' equity$57.96M$61.65M$106.18M$169.32M$175.60M
Shares outstanding5.28M5.19M37.83M37.84M32.13M
Cash flow statement
Operating cash flow-$29.81M-$49.28M-$60.27M-$57.28M-$45.53M
Capital expenditure—$0$12,000$54,000$333,000
Free cash flow—-$49.28M-$60.28M-$57.34M-$45.87M
Investing cash flow$47.27M$33.49M$27.66M-$112.17M-$2.33M
Financing cash flow$16,000$5.20M$143,000$51.08M$82.97M
Depreciation & amortization$92,000$131,000$150,000$167,000$109,000
Stock-based compensation$5.31M$7.99M$10.92M$9.50M$3.65M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.